{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:01:30Z","timestamp":1781481690220,"version":"3.54.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1097\/rlu.0000000000000533","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T07:41:27Z","timestamp":1406360487000},"page":"855-861","source":"Crossref","is-referenced-by-count":15,"title":["A Frequency and Semiquantitative Analysis of Pathological 68Ga DOTATATE PET\/CT Uptake by Primary Site\u2013Dependent Neuroendocrine Tumor Metastasis"],"prefix":"10.1097","volume":"39","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kolasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Miko\u0142ajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210204","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R2-1-20210204","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy.","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"R3-1-20210204","first-page":"1704","article-title":"Peptide receptor imaging and therapy.","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J Nucl Med"},{"key":"R4-1-20210204","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00259-006-0113-7","article-title":"99mTc-EDDAHYNIC octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years experience.","volume":"33","author":"Hubalewska-Dydejczyk","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-1-20210204","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1016\/j.dld.2003.11.024","article-title":"Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours.","volume":"36","author":"Gibril","year":"2004","journal-title":"Dig Liver Dis"},{"key":"R6-1-20210204","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.01.013","article-title":"Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging.","volume":"23","author":"Dromain","year":"2005","journal-title":"J Clin Oncol"},{"key":"R8-1-20210204","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00259-004-1702-y","article-title":"Radiolabelling DOTA-peptides with Ga-68.","volume":"32","author":"Breeman","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R9-1-20210204","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2967\/jnumed.109.066134","article-title":"The role of Ga-68-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.","volume":"51","author":"Srirajkanthan","year":"2010","journal-title":"J Nucl Med"},{"key":"R10-1-20210204","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"Ga68-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT.","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"},{"key":"R11-1-20210204","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11307-010-0374-1","article-title":"Ga-68-DOTA-NOC PETCT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan).","volume":"13","author":"Krausz","year":"2011","journal-title":"Mol Imaging Biol"},{"key":"R12-1-20210204","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of Ga-68-DOTATOC positron emission tomographycomputed tomography on multimodal management of patients with neuroendocrine tumors.","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg"},{"key":"R13-1-20210204","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.2967\/jnumed.108.060236","article-title":"Bone metastases in patients with neuroendocrine tumor: Ga-68-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.","volume":"50","author":"Putzer","year":"2009","journal-title":"J Nucl Med"},{"key":"R14-1-20210204","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.109.071712","article-title":"Ga-68-DOTANOC PETCT clinical impact in patients with neuroendocrine tumors.","volume":"51","author":"Ambrossini","year":"2010","journal-title":"J Nucl Med"},{"key":"R15-1-20210204","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00259-007-0587-y","article-title":"Ga-68-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.","volume":"35","author":"Pettino","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R16-1-20210204","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1097\/RLU.0b013e31825b2555","article-title":"Clinical nuclear medicine semiquantitative analysis and characterization of physiological biodistribution of Ga-68-DOTA-TATE PETCT.","volume":"37","author":"Kunikowska","year":"2012","journal-title":"Clin Nucl Med"},{"key":"R17-1-20210204","first-page":"61","article-title":"Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions.","volume":"54","author":"Prasad","year":"2010","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R18-1-20210204","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/MNM.0b013e32833f635e","article-title":"Distribution pattern of Ga-68-DOTATATE in disease-free patients.","volume":"31","author":"Shastry","year":"2010","journal-title":"Nucl Med Commun"},{"key":"R19-1-20210204","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s00259-008-0944-5","article-title":"Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in Ga-68 DOTATOC PETCT.","volume":"36","author":"Miederer","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-1-20210204","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s00259-011-1846-5","article-title":"Molecular imaging with Ga-68 Normal uptake patterns and potential pitfalls is highly important to differentiate sites of disease from normal physiological uptake and it is necessary for accurate interpretation a-SSTR PETCT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.","volume":"38","author":"Kaemmerer","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R21-1-20210204","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s00259-011-1760-x","article-title":"Ga-68-DOTATOC PETCT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax.","volume":"38","author":"Boy Ch, Heusner","year":"2011","journal-title":"Eur J Nucl Med"},{"key":"R22-1-20210204","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","article-title":"Ga-68-DOTATOC versus Ga-68-DOTATATE PETCT in functional imaging of neuroendocrine tumors.","volume":"52","author":"Poeppel","year":"2011","journal-title":"J Nucl Med"},{"key":"R23-1-20210204","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s00259-012-2309-3","article-title":"68Ga-DOTA-TOC uptake in neuro endocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PETCT.","volume":"40","author":"Kroiss","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R24-1-20210204","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00259-008-1030-8","article-title":"Intraindividual comparison of Ga-68-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumors.","volume":"36","author":"Haug","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-1-20210204","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00259-008-0769-2","article-title":"Comparison between Ga-68-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumors.","volume":"35","author":"Ambrosini","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-1-20210204","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00259-009-1349-9","article-title":"68Ga-DOTA-NOC PETCT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.","volume":"37","author":"Ambrosini","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R27-1-20210204","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000051856","article-title":"Natural history of neurendocrine enteropancreatic tumors.","volume":"62","author":"Mignon","year":"2000","journal-title":"Digestion"},{"key":"R28-1-20210204","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00535-012-0540-0","article-title":"Analysis of lymph node metastasis in pancreatic neuroendocrine tumors (PNENs) based on the tumor size and hormonal production.","volume":"47","author":"Tsutsumi","year":"2012","journal-title":"J Gastroenterol"},{"key":"R29-1-20210204","first-page":"2005","article-title":"Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours Eur J Nucl Med Mol Imaging.","volume":"38","author":"Al-Ibraheem","year":"2011","journal-title":""},{"key":"R30-1-20210204","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog 177 Lu-DOTA 0,Tyr3 octreotate: toxicity, efficacy, and survival.","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J Clin Oncol"},{"key":"R31-1-20210204","first-page":"1788","article-title":"Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y177Lu-DOTATATE: which is a better therapy option Eur J Nucl Med Mol Imaging.","volume":"38","author":"Kunikowska","year":"2011","journal-title":""},{"key":"R32-1-20210204","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.2967\/jnumed.110.075002","article-title":"68Ga-DOTATATE PETCT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors.","volume":"51","author":"Haug","year":"2010","journal-title":"J Nucl Med"},{"key":"R33-1-20210204","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2967\/jnumed.108.053421","article-title":"68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.","volume":"50","author":"Gabriel","year":"2009","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00003072-201410000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T07:09:06Z","timestamp":1618038546000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003072-201410000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000000533","relation":{},"ISSN":["0363-9762"],"issn-type":[{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}